A- A A+

Cannabis Use and Hypomania in Young People: A Prospective Analysis

Steven Marwaha, Catherine Winsper, Paul Bebbington, Daniel Smith,

Schizophrenia Bulletin, sbx158, doi.org/10.1093/schbul/sbx158

https://academic.oup.com/schizophreniabulletin/advance-article/doi/10.1093/schbul/sbx158/4668709

Case report: surgical removal of a migrated needle in right ventricle of an intravenous drug user

Xianming Fu, Kai Chen, Xiaobo Liao and Kangjun Shen

Substance Abuse Treatment, Prevention, and Policy, 2017, 12:51, doi.org/10.1186/s13011-017-0134-1

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-017-0134-1

Schizophrenie: Avatartherapie schwächt akustische Halluzinationen

London – Ein persönlicher Avatar, über den Schizophreniepatienten in einen persön­lichen Dialog mit den Stimmen eintreten, die sie bedrohen, hat in einer randomisierten Studie in Lancet Psychiatry (2017; doi: 10.1016/S2215-0366(17)30427-3) den Patienten besser geholfen als ein unterstützendes Gespräch mit dem Therapeuten. (aerzteblatt.de, 28.11.2017)

https://www.aerzteblatt.de/nachrichten/83651/Schizophrenie-Avatartherapie-schwaecht-akustische-Halluzinationen

Dysrhythmias with Loperamide Used for Opioid Withdrawal.

Vithalani ND, Heron C, Rao RE, Cardell AF, Stephens MB.

J Am Board Fam Med. 2017 Nov-Dec;30(6):832-834. doi: 10.3122/jabfm.2017.06.170066.

http://www.jabfm.org/content/30/6/832.long

AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial

Tom KJ Craig, Mar Rus-Calafell, Thomas Ward, Julian P Leff, Mark Huckvale, Elizabeth Howarth, Richard Emsley, Philippa A Garety

Lancet Psychiatry, 2017, Published Online November 23, 2017, doi.org/10.1016/S2215-0366(17)30427-3

http://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(17)30427-3.pdf

Psychosen: Inzidenz schwankt international sehr stark

London – Die verbreitete Ansicht, dass Schizophrenien und andere Psychosen in allen Ländern gleich häufig auftreten, ist offenbar nicht korrekt. Eine Studie in JAMA Psychiatry (2017; doi: 10.1001/jamapsychiatry.2017.3554) ermittelt deutliche Schwankungen zwischen 17 Regionen, davon 16 in Europa, die auf starke soziale Einflüsse hinweisen. (aerzteblatt.de, 07.12.2017)

https://www.aerzteblatt.de/nachrichten/86905/Psychosen-Inzidenz-schwankt-international-sehr-stark

Altered Brain Developmental Trajectories in Adolescents After Initiating Drinking.

Pfefferbaum A, Kwon D, Brumback T, Thompson WK, Cummins K, Tapert SF, Brown SA, Colrain IM, Baker FC, Prouty D, De Bellis MD, Clark DB, Nagel BJ, Chu W, Park SH, Pohl KM, Sullivan EV.

Am J Psychiatry. 2017 Oct 31:appiajp201717040469. doi: 10.1176/appi.ajp.2017.17040469.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29084454

Risk of respiratory depression with opioids and concomitant gabapentinoids.

Savelloni J, Gunter H, Lee KC, Hsu C, Yi C, Edmonds KP, Furnish T, Atayee RS.

J Pain Res. 2017 Nov 10;10:2635-2641. doi: 10.2147/JPR.S144963.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691933/

Allgemeinmediziner stellen S3-Leitlinie zur Multimorbidität vor

Frankfurt am Main – Eine Leitlinie auf S3-Niveau zum Thema Multimorbidität hat die Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) vorgestellt. Die Fachgesellschaft betont, Multimorbidität sei eine der zentralen Anforderungen für Hausärzte in der Praxis. „Anstatt die vielen einzelnen Leitlinien separat zu konsultieren, möchten wir mit der neuen Leitlinie das große Ganze in den Mittelpunkt rücken“, erklärte der Erstautor und Sprecher der ständigen Leitlinienkommission, Martin Scherer, der auch Vizepräsident der DEGAM ist. (aerzteblatt.de, 23.11.2017)

https://www.aerzteblatt.de/nachrichten/83628/Allgemeinmediziner-stellen-S3-Leitlinie-zur-Multimorbiditaet-vor

Drug use and drug-related infections among prisoners in Europe

Linda Montanari, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6971/14H30_1_Linda Montanari.pptx

The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis.

Litz M, Leslie D.

Am J Addict. 2017 Dec;26(8):859-863. doi: 10.1111/ajad.12644. Epub 2017 Nov 16.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29143483

The German version of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): psychometric properties and diagnostic utility.

Krüger-Gottschalk A, Knaevelsrud C, Rau H, Dyer A, Schäfer I, Schellong J, Ehring T.

BMC Psychiatry. 2017 Nov 28;17(1):379. doi: 10.1186/s12888-017-1541-6.

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-017-1541-6

Pediatric Death Due to Myocarditis After Exposure to Cannabis

Nappe, Thomas M., Hoyte, Christopher O.

Clinical Practice and Cases in Emergency Medicine, Volume 1, Issue 3

Abstract

https://escholarship.org/uc/item/1n10w5pc#main

Rauchen - Das größte vermeidbare Gesundheitsrisiko Deutschlands

Nach wie vor stirbt in Deutschland mehr als jeder achte Mensch an den Folgen des Rauchens. Seit zehn Jahren versucht die Regierung intensiv, die Bürger davor zu schützen. Was haben die Gesetze gebracht? (spiegel online, 01.12.2017)

http://www.spiegel.de/gesundheit/diagnose/rauchen-das-groesste-vermeidbare-gesundheitsrisiko-deutschlands-a-1181208.html

Drug-related infectious diseases in Europe: update from the EMCDDA expert network (2017)

Summary

This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting, held in Lisbon in June 2017, which brought together national experts from the 28 EU Member States, Norway, Turkey, European neighbourhood countries and partner organisations. (EMCDDA, Lissabon, November 2017)

http://www.emcdda.europa.eu/rapid-communications/2017/drug-related-infectious-diseases-in-europe_en

Understanding AVATAR therapy: who, or what, is changing?

Alderson-Day, Ben et al.

The Lancet Psychiatry , Volume 0 , Issue 0 , Published online: November 23, 2017, doi.org/10.1016/S2215-0366(17)30471-6
http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30471-6/fulltext

Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis

Aldridge, Robert W et al.

The Lancet , Volume 0 , Issue 0 , Published: 11 November 2017, doi.org/10.1016/S0140-6736(17)31869-X

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31869-X/fulltext

UK. Shooting Up: infections among people who inject drugs in the UK

This Public Health England report describes the extent of infections among people who inject drugs (PWID) in the United Kingdom. (PHE, UK, Published: 1 November 2013; Last updated: 29 November 2017)

https://www.gov.uk/government/publications/shooting-up-infections-among-people-who-inject-drugs-in-the-uk

Estimates are not enough: scaling-up interventions to improve the health of people who inject drugs

Prins, Maria et al.

The Lancet Global Health , Volume 5 , Issue 12 , e1162 - e1163

http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30430-8/fulltext

EMCDDA. Systematic review on active case finding of communicable diseases in prison settings

Summary

A higher prevalence of communicable diseases among people in prison compared with the general public is recognised as a public health issue as well as a major concern for the people affected, as the majority of incarcerated people return to their communities. Active case finding is a key prevention measure to promote early diagnosis, treatment and to prevent further disease transmission. The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region. The communicable diseases targeted by this review were not selected a priori, but identified through the retrieved evidence. (EMCDDA/ECDC, November 2017)

http://www.emcdda.europa.eu/joint-publications/ecdc/communicable-diseases-prisons_en